Haaijer-Ruskamp FM - Search Results

1

Impact of safety-related regulatory action on clinical practice: a systematic review.

Piening S, Haaijer-Ruskamp FM, de Vries JT, van der Elst ME, de Graeff PA, Straus SM, Mol PG. Piening S, et al. Drug Saf. 2012 May 1;35(5):373-85. doi: 10.2165/11599100-000000000-00000. Drug Saf. 2012. PMID: 22480319 Review.

2

Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands.

Piening S, Haaijer-Ruskamp FM, de Graeff PA, Straus SM, Mol PG. Piening S, et al. Drug Saf. 2012 Nov 1;35(11):1061-72. doi: 10.1007/BF03261992. Drug Saf. 2012. PMID: 23061782

3

Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire.

de Vries ST, Mol PG, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. de Vries ST, et al. Drug Saf. 2013 Sep;36(9):765-77. doi: 10.1007/s40264-013-0036-8. Drug Saf. 2013. PMID: 23553447 Clinical Trial.

4

The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the Netherlands.

Piening S, de Graeff PA, Straus SM, Haaijer-Ruskamp FM, Mol PG. Piening S, et al. Drug Saf. 2013 Sep;36(9):723-31. doi: 10.1007/s40264-013-0079-x. Drug Saf. 2013. PMID: 23797603 Clinical Trial.

5

Post-approval safety issues with innovative drugs: a European cohort study.

Mol PG, Arnardottir AH, Motola D, Vrijlandt PJ, Duijnhoven RG, Haaijer-Ruskamp FM, de Graeff PA, Denig P, Straus SM. Mol PG, et al. Drug Saf. 2013 Nov;36(11):1105-15. doi: 10.1007/s40264-013-0094-y. Drug Saf. 2013. PMID: 24048690

6

Reliability of the assessment of preventable adverse drug events in daily clinical practice.

van Doormaal JE, Mol PG, van den Bemt PM, Zaal RJ, Egberts AC, Kosterink JG, Haaijer-Ruskamp FM. van Doormaal JE, et al. Pharmacoepidemiol Drug Saf. 2008 Jul;17(7):645-54. doi: 10.1002/pds.1586. Pharmacoepidemiol Drug Saf. 2008. PMID: 18338767

7

A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Mol PG, Straus SM, Piening S, de Vries JT, de Graeff PA, Haaijer-Ruskamp FM. Mol PG, et al. Drug Saf. 2010 Jun 1;33(6):463-74. doi: 10.2165/11532840-000000000-00000. Drug Saf. 2010. PMID: 20486729

8

Additional safety risk to exceptionally approved drugs in Europe?

Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, Eichler HG, de Graeff PA, Mol PG. Arnardottir AH, et al. Br J Clin Pharmacol. 2011 Sep;72(3):490-9. doi: 10.1111/j.1365-2125.2011.03995.x. Br J Clin Pharmacol. 2011. PMID: 21501215 Free PMC article.

9

Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands.

Dequito AB, Mol PG, van Doormaal JE, Zaal RJ, van den Bemt PM, Haaijer-Ruskamp FM, Kosterink JG. Dequito AB, et al. Drug Saf. 2011 Nov 1;34(11):1089-100. doi: 10.2165/11592030-000000000-00000. Drug Saf. 2011. PMID: 21981436

10

Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.

Arnardottir AH, Haaijer-Ruskamp FM, Straus SM, de Graeff PA, Mol PG. Arnardottir AH, et al. Drug Saf. 2011 Nov 1;34(11):1101-14. doi: 10.2165/11592060-000000000-00000. Drug Saf. 2011. PMID: 21981437

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

168 results

Search Page

Filters